Republican lawmakers are raising concerns that companies may face environmental barriers to manufacturing more pharmaceuticals and active pharmaceutical ingredients in the US, as the idea of onshoring gains popularity as an option for relieving generic drug shortages.
Environmental Regulations May Create Barriers To Onshoring More Rx Manufacturing
The House Ways and Means Committee may take more of a kitchen sink approach to addressing drug shortages than other congressional committees that have been primarily focused on paying for quality. Hearing witnesses said Congress must follow through on funding incentives for US onshoring.
More from Manufacturing
More from Compliance
• By
A global collaborative inspections pilot reduced the number of individual inspections for participating manufacturing facilities, demonstrating that multiple regulatory authorities can carry out joint inspections using a mix of on-site and remote approaches.
• By
The UK’s medicines regulator is pressing on with clarifying its expectations on decentralized manufacturing of medicines.
• By
Sponsors should review longstanding agency concepts on consumer-friendly language and claims limitations, along with Office of Prescription Drug Promotion research and enforcement, when applying the 2018 CFL guidance to direct-to-consumer advertising, Sidley Austin’s Cope says.